コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 multiple myeloma, and T-cell large granular lymphocytic leukaemia).
2 ne-kinase inhibitor with activity in chronic lymphocytic leukaemia.
3 patients with relapsed or refractory chronic lymphocytic leukaemia.
4 n patients with previously untreated chronic lymphocytic leukaemia.
5 urther advance treatment of del(17p) chronic lymphocytic leukaemia.
6 tuximab 500 mg/m(2) in patients with chronic lymphocytic leukaemia.
7 with relapsed or refractory del(17p) chronic lymphocytic leukaemia.
8 hysically fit patients with advanced chronic lymphocytic leukaemia.
9 iagnostic criteria for T cell large granular lymphocytic leukaemia.
10 treatment regimen for patients with chronic lymphocytic leukaemia.
11 re-induction treatment for relapsed chronic lymphocytic leukaemia.
12 fficacy as monotherapy in refractory chronic lymphocytic leukaemia.
13 cohesion, is recurrently mutated in chronic lymphocytic leukaemia.
14 atients aged 65 years and older with chronic lymphocytic leukaemia.
15 e and are found in cancers including chronic lymphocytic leukaemia.
16 atients with chronic granulocytic or chronic lymphocytic leukaemia.
17 nts with treatment-naive symptomatic chronic lymphocytic leukaemia.
18 or two patients with Down syndrome and acute lymphocytic leukaemia.
19 well tolerated frontline therapy for chronic lymphocytic leukaemia.
20 e effective for previously untreated chronic lymphocytic leukaemia.
21 prognostic factors in two series of chronic lymphocytic leukaemia.
22 ously treated relapsed or refractory chronic lymphocytic leukaemia.
23 rst-line treatment for patients with chronic lymphocytic leukaemia.
24 patients with ABL-class fusion B-cell acute lymphocytic leukaemia.
25 nt of patients with Ph-negative B-cell acute lymphocytic leukaemia.
26 n patients with previously untreated chronic lymphocytic leukaemia.
27 lored in patients with newly diagnosed acute lymphocytic leukaemia.
28 the setting of relapsed or refractory acute lymphocytic leukaemia.
29 ble exceptions of Hodgkin lymphoma and acute lymphocytic leukaemia.
30 survival in older patients with B-cell acute lymphocytic leukaemia.
31 rapy for both children and adults with acute lymphocytic leukaemia.
32 r patients with previously untreated chronic lymphocytic leukaemia.
33 n patients with relapsed or refractory acute lymphocytic leukaemia.
34 or who have had previous therapy for chronic lymphocytic leukaemia.
35 nicity, but are not observed in T-cell acute lymphocytic leukaemia.
36 ith relapsed or refractory high-risk chronic lymphocytic leukaemia.
37 Hodgkin lymphoma, retinoblastoma, and acute lymphocytic leukaemia.
38 rapy for relapsed or refractory B-cell acute lymphocytic leukaemia.
39 with CNS relapsed or refractory B-cell acute lymphocytic leukaemia.
40 re standard first-line treatments in chronic lymphocytic leukaemia.
41 e development of clinically apparent chronic lymphocytic leukaemia.
42 mab in patients with treatment-naive chronic lymphocytic leukaemia.
43 or younger with previously untreated chronic lymphocytic leukaemia.
44 with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia.
45 with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia.
46 n patients with refractory or relapsed acute lymphocytic leukaemia.
47 sponses in younger fit patients with chronic lymphocytic leukaemia.
48 aive patients (aged >=18 years) with chronic lymphocytic leukaemia.
49 t-naive patients with IGHV-unmutated chronic lymphocytic leukaemia.
50 unotherapy regimen for patients with chronic lymphocytic leukaemia.
51 patients with relapsed or refractory chronic lymphocytic leukaemia.
52 nib has transformed the treatment of chronic lymphocytic leukaemia.
53 in patients with previously treated chronic lymphocytic leukaemia.
54 patients with relapsed or refractory chronic lymphocytic leukaemia.
55 ted in familial glioma, melanoma and chronic lymphocytic leukaemia.
56 patients with relapsed or refractory chronic lymphocytic leukaemia.
57 as no increase in SPM in lymphoma or chronic lymphocytic leukaemia (0.90 [0.76-1.08]) and myelodyspla
58 r (CAR) T cells in two patients with chronic lymphocytic leukaemia(1-4) who achieved a complete remis
59 and adolescents with Down syndrome and acute lymphocytic leukaemia, 136 were eligible for analyses an
60 patients with relapsed or refractory chronic lymphocytic leukaemia (180 [70%] were male; 252 [98%] we
62 lation per International Workshop on Chronic Lymphocytic Leukaemia 2008 response criteria modified fo
65 ar for patients with Down syndrome and acute lymphocytic leukaemia (52 [38%] of 136) and matched cont
66 ibrutinib (420 mg for patients with chronic lymphocytic leukaemia; 560 mg for patients with B-cell n
67 ewly diagnosed ABL-class fusion B-cell acute lymphocytic leukaemia (77 from European study groups, 25
68 older with a documented diagnosis of chronic lymphocytic leukaemia according to the 2008 Internationa
69 patients with relapsed or refractory chronic lymphocytic leukaemia (according to the 2008 Modified In
71 x has a high anti-tumour activity in chronic lymphocytic leukaemia, achieving deep remissions by pote
72 Treatment-naive fit patients with chronic lymphocytic leukaemia (aged 33-81 years) without del(17p
75 igen receptor (CAR) T cell therapy for acute lymphocytic leukaemia (ALL)(1-3), approximately 50% of p
76 8-64 years with previously untreated chronic lymphocytic leukaemia and a cumulative illness rating sc
77 se series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibil
78 ith encouraging activity in advanced chronic lymphocytic leukaemia and B-cell non-Hodgkin lymphoma.
79 patients with relapsed or refractory chronic lymphocytic leukaemia and could allow some patients to m
80 ve for patients with Down syndrome and acute lymphocytic leukaemia and for matched patients without D
81 he treatment of patients with del17p chronic lymphocytic leukaemia and has been incorporated into tre
83 pecific for tumour cells but primary chronic lymphocytic leukaemia and mantle cell lymphoma (MCL) cel
84 GH and AID off-target sites in human chronic lymphocytic leukaemia and mantle cell lymphoma cell line
85 and active in relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma, with a r
87 etween patients with Down syndrome and acute lymphocytic leukaemia and matched controls, and the seco
89 ged 1-23 years) with Down syndrome and acute lymphocytic leukaemia and matched non-Down syndrome pati
90 from two different types of cancer, chronic lymphocytic leukaemia and medulloblastoma, we conduct a
91 ious triumphs, for instance in cure of acute lymphocytic leukaemia and other childhood cancers, Hodgk
92 ctive in relapsed or refractory B-cell acute lymphocytic leukaemia and results in high rates of minim
93 r evaluation of the BOVen regimen in chronic lymphocytic leukaemia and small lymphocytic lymphoma wit
94 ow become the standard treatment for chronic lymphocytic leukaemia and the basis for new protocols th
95 , 2012, we enrolled 29 patients with chronic lymphocytic leukaemia and two patients with small lympho
97 iladelphia-chromosome negative, B-cell acute lymphocytic leukaemia, and an ECOG performance status of
98 ged 18 years or older, had untreated chronic lymphocytic leukaemia, and coexisting conditions with a
99 , is frequently rearranged in B-cell chronic lymphocytic leukaemia, and contains the DAOA locus assoc
100 ed 18 years or older, diagnosed with chronic lymphocytic leukaemia, and currently taking BTKi therapy
101 m toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities s
102 ly 3% of children with newly diagnosed acute lymphocytic leukaemia, and studies suggest that leukaemi
103 both, in patients with newly diagnosed acute lymphocytic leukaemia, and these approaches are emerging
104 with non-Hodgkin B-cell lymphoma and chronic lymphocytic leukaemia; and evaluation of the anti-glycop
106 sion body myositis and T cell large granular lymphocytic leukaemia are rare diseases involving pathog
107 alth tradeoff for cure using childhood acute lymphocytic leukaemia as a model disease, the prioritise
108 with del(17p) relapsed or refractory chronic lymphocytic leukaemia (as defined by 2008 Modified Inter
109 factors are also expressed in human chronic lymphocytic leukaemia B cells and in a B-1-like populati
110 malignant cells from patients with B-chronic lymphocytic leukaemia (B-CLL) and of normal B lymphocyte
113 The molecular classification of chronic lymphocytic leukaemia based on B-cell receptor immunoglo
114 nt-line therapy in fit patients with chronic lymphocytic leukaemia, but bendamustine and rituximab is
115 rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for per
117 RD in the bone marrow (defined as <1 chronic lymphocytic leukaemia cell per 10 000 leucocytes as meas
118 (flow cytometry cutoff less than one chronic lymphocytic leukaemia cell per 10 000 leukocytes [<10(-4
119 it has been shown to be expressed on chronic lymphocytic leukaemia cells and on the surface of newly
120 y induce apoptosis in MOLT-4 and Jurkat E6 T lymphocytic leukaemia cells following intracytoplasmic d
121 II, which is a phenotypic feature of chronic lymphocytic leukaemia cells, can skew B cell development
122 In Philadelphia chromosome-positive acute lymphocytic leukaemia, chemotherapy-free regimens combin
123 hrough whole-exome sequencing of 538 chronic lymphocytic leukaemia (CLL) and matched germline DNA sam
124 understanding of disease biology of chronic lymphocytic leukaemia (CLL) and the development of novel
126 togenetics represent the majority of chronic lymphocytic leukaemia (CLL) cases, yet have relatively f
127 nds play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective m
130 ent genome-wide association study of chronic lymphocytic leukaemia (CLL) has identified a susceptibil
131 ovided only a partial explanation of chronic lymphocytic leukaemia (CLL) heterogeneity, and since con
132 treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) in combination with rituxima
145 121 efficacy evaluable patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphom
148 used the indolent growth dynamics of chronic lymphocytic leukaemia (CLL) to analyse the growth rates
149 n patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which co
150 Neoplastic cells from patients with chronic lymphocytic leukaemia (CLL) were cultured in the presenc
151 patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who are on targeted therapie
152 the quality of life of patients with chronic lymphocytic leukaemia (CLL) who do not require systemic
154 bone marrow for leukaemia excluding chronic lymphocytic leukaemia (CLL), as well as subtypes of leuk
155 ion factor that has been linked with chronic lymphocytic leukaemia (CLL), but its functions in CLL ma
159 nces in the proportion of cases with chronic lymphocytic leukaemia (CLL)-phenotype MBL and CD5-negati
167 d genome-wide association studies of chronic lymphocytic leukaemia (CLL, N = 1,842), Hodgkin lymphoma
168 some 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when t
169 udy in patients with treatment-naive chronic lymphocytic leukaemia done at 142 academic and community
170 y (limited to follicular lymphoma or chronic lymphocytic leukaemia during dose escalation) and an Eas
171 ve, and PDGFRB fusion-positive) B-cell acute lymphocytic leukaemia enrolled in clinical trials of mul
172 t-naive patients with IGHV-unmutated chronic lymphocytic leukaemia enrolled on the CLL8 trial of the
173 lymphoma, rheumatoid arthritis, and chronic lymphocytic leukaemia (Europe only); multiple sclerosis
174 ticularly in patients with high-risk chronic lymphocytic leukaemia features or who have had previous
176 gkin lymphoma, rheumatoid arthritis, chronic lymphocytic leukaemia, granulomatosis with polyangiitis,
179 s or older with previously untreated chronic lymphocytic leukaemia, had an ECOG performance status of
180 occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is
181 ong treatment-free survival (TFS) in chronic lymphocytic leukaemia have been investigated, most have
182 sions of relapsed or refractory B-cell acute lymphocytic leukaemia have been observed following treat
183 Children with ABL-class fusion B-cell acute lymphocytic leukaemia have poor outcomes when treated wi
184 Patients with 17p deletion (del17p) chronic lymphocytic leukaemia have poor responses and survival a
185 rall survival in young patients with chronic lymphocytic leukaemia; however, its application in elder
186 al for treatment-naive patients with chronic lymphocytic leukaemia in 109 centres in 16 countries.
187 atients with non-Hodgkin lymphoma or chronic lymphocytic leukaemia in 2009, updated and diligent phar
189 130 centres in 24 countries who had chronic lymphocytic leukaemia in complete or partial remission a
191 nt groups (one [2%] patient with fatal acute lymphocytic leukaemia in the lenalidomide group and one
192 patients with ABL-class fusion B-cell acute lymphocytic leukaemia in the pre-tyrosine-kinase inhibit
193 e different mutational precursors of chronic lymphocytic leukaemia (including trisomy 12, loss of chr
194 patients with relapsed or refractory chronic lymphocytic leukaemia, including BCRi-pretreated patient
195 e highly effective in the treatment of acute lymphocytic leukaemia, including the anti-CD22 antibody-
196 brutinib is active for patients with chronic lymphocytic leukaemia irrespective of IGHV mutation stat
198 outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger pat
202 nhibitors (BTKi) have revolutionised chronic lymphocytic leukaemia management; however, therapy impai
203 many B cell malignancies, including chronic lymphocytic leukaemia, mantle cell lymphoma, diffuse lar
204 atched non-Down syndrome patients with acute lymphocytic leukaemia (matched controls) from eight tria
206 uish the related overt malignancies (chronic lymphocytic leukaemia, multiple myeloma, and T-cell larg
207 ven at least one dose of study drug (chronic lymphocytic leukaemia, n=21; mantle cell lymphoma, n=21)
208 ere restricted to patients with B-cell acute lymphocytic leukaemia, no differences in event-free surv
209 strategies in patients with relapsed chronic lymphocytic leukaemia, notably in the present era of tar
210 utinib orally once daily (420 mg for chronic lymphocytic leukaemia or 560 mg for mantle cell lymphoma
211 h relapsed or refractory CD19-positive acute lymphocytic leukaemia or lymphocytic lymphoma from five
212 ith relapsed or refractory high-risk chronic lymphocytic leukaemia or mantle cell lymphoma often do n
213 nd older with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma, with an E
214 years or older with histologically confirmed lymphocytic leukaemia or relapsed or refractory B-cell n
216 ts: relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del
217 ith relapsed or refractory high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma (del
218 or older with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma and
219 atients had a confirmed diagnosis of chronic lymphocytic leukaemia or small lymphocytic lymphoma as p
220 Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for
221 n previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma inde
222 7 previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma reac
223 ears) with previously treated del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma rece
225 least 65 years, and had symptomatic chronic lymphocytic leukaemia or small lymphocytic lymphoma requ
226 The median time from diagnosis of chronic lymphocytic leukaemia or small lymphocytic lymphoma to R
227 nsored, phase 2 study, patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma were
228 onsisted of 144 patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma who
229 (>/=18 years of age) who had active chronic lymphocytic leukaemia or small lymphocytic lymphoma with
230 (61%) of 36 patients with high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13
231 n patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, eit
232 orted with single-agent ibrutinib in chronic lymphocytic leukaemia or small lymphocytic lymphoma, fol
233 patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma, inc
234 y cohort if they had treatment-naive chronic lymphocytic leukaemia or small lymphocytic lymphoma, req
235 st difficult subset of patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma.
236 d or refractory patients with del17p chronic lymphocytic leukaemia or small lymphocytic lymphoma.
237 in patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma.
238 ucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma.
239 homa to 19 (53%) of 36 patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; inc
240 in the dose-escalation cohort (n=14 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=1
241 22 in the dose-expansion cohort (n=9 chronic lymphocytic leukaemia or small lymphocytic lymphoma; n=1
242 untreated patients with symptomatic chronic lymphocytic leukaemia, or small lymphocytic lymphoma is
244 tial disparities in outcome for B-cell acute lymphocytic leukaemia persist by race and ethnicity, but
246 with relapsed or refractory del(17p) chronic lymphocytic leukaemia, providing a new therapeutic optio
247 Previous studies of patients with chronic lymphocytic leukaemia reported high response rates to fl
248 ells for relapsed or refractory B-cell acute lymphocytic leukaemia, reported between Jan 1, 2012, and
249 e 0-2 and had relapsed or refractory chronic lymphocytic leukaemia requiring treatment according to t
251 8 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measur
252 ay on day 15 of cycle 1 according to chronic lymphocytic leukaemia schedule, then 400 mg/day from day
253 viously treated B-cell malignancies (chronic lymphocytic leukaemia, small lymphocytic lymphoma, mantl
254 a (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SL
255 n adults with relapsed or refractory chronic lymphocytic leukaemia, stratified by previous exposure t
256 lled on the CLL8 trial of the German Chronic Lymphocytic Leukaemia Study Group who were treated betwe
257 gy, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiati
258 n patients with previously untreated chronic lymphocytic leukaemia, supporting its use as a first-lin
261 y of the 2000 mg dose established in chronic lymphocytic leukaemia, the study was amended on Dec 9, 2
262 T, although they could have received chronic lymphocytic leukaemia therapies; were aged 18 years or o
263 s had received at least one previous chronic lymphocytic leukaemia therapy and had an Eastern Coopera
264 tyrosine kinase inhibitor are changing acute lymphocytic leukaemia therapy, highlighting the potentia
265 erm disease-control in patients with chronic lymphocytic leukaemia, they need to be combined with BCL
266 rituximab should allow patients with chronic lymphocytic leukaemia to receive clinical benefit from t
267 analyse the outcomes of patients with acute lymphocytic leukaemia treated with anti-CD19 CAR T cells
268 ed combination regimen for frontline chronic lymphocytic leukaemia treatment in younger fit patients.
269 dverse events (four pneumonia, three chronic lymphocytic leukaemia, two Richter's syndrome, two sepsi
270 hest ever published in patients with chronic lymphocytic leukaemia unrestricted by prognostic marker
271 69 [0.8%] of 8426), Down syndrome and acute lymphocytic leukaemia was associated with a higher risk
272 elphia chromosome (Ph)-negative B-cell acute lymphocytic leukaemia were eligible, including patients
273 , and May 23, 2019, 37 patients with chronic lymphocytic leukaemia were enrolled and all received at
274 and Sept 29, 2015, 314 patients with chronic lymphocytic leukaemia were enrolled and randomly assigne
275 patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled from 15 sites across
276 en, adolescents, and young adults with acute lymphocytic leukaemia were enrolled, of which 21 152 had
278 patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled; 13 (29%) were femal
279 113 patients with Down syndrome and acute lymphocytic leukaemia were excluded from matching in acc
280 ged 18 years or older with untreated chronic lymphocytic leukaemia were randomly assigned, via an int
281 8 previously untreated patients with chronic lymphocytic leukaemia were screened for the study; 379 (
282 8 patients with newly diagnosed B-cell acute lymphocytic leukaemia were treated (median age 37 years
283 Patients were eligible if they had chronic lymphocytic leukaemia; were aged 18 years or older; had
284 nces predicted the relative rates of chronic lymphocytic leukaemia (which is more common among Europe
285 solidation strategy in patients with chronic lymphocytic leukaemia, which could improve survival.
287 tients with recurrent or progressive chronic lymphocytic leukaemia who are in complete or partial res
288 afety of venetoclax in patients with chronic lymphocytic leukaemia who are refractory to or relapse d
289 gression in first-line patients with chronic lymphocytic leukaemia who do not achieve minimal residua
290 e treatment option for patients with chronic lymphocytic leukaemia who do not have access to kinase i
291 ith previously untreated progressive chronic lymphocytic leukaemia who had an Eastern Cooperative Onc
292 t-naive patients with IGHV-unmutated chronic lymphocytic leukaemia who might substantially benefit fr
294 ile in treatment-naive patients with chronic lymphocytic leukaemia who were elderly or had comorbidit
295 n patients with previously untreated chronic lymphocytic leukaemia who were older or had comorbiditie
296 tients with acute myeloid leukaemia or acute lymphocytic leukaemia, who received a HSCT at any age fr
297 patients with relapsed or refractory chronic lymphocytic leukaemia whose disease progressed during or
298 with immunophenotypically confirmed chronic lymphocytic leukaemia with active disease, who responded
300 ual disease identifies patients with chronic lymphocytic leukaemia with poor outcome after first-line